165 related articles for article (PubMed ID: 33459955)
1. Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa.
Moloi MW; Rusch JA; Omar F; Ekrikpo U; Dandara C; Bello AK; Jayne D; Okpechi IG
Int Urol Nephrol; 2021 Sep; 53(9):1865-1873. PubMed ID: 33459955
[TBL] [Abstract][Full Text] [Related]
2. Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (uTWEAK) and Urinary Monocyte Chemo-attractant Protein-1 (uMCP-1): Promising Biomarkers of Lupus Nephritis Activity?
Elsaid DS; Abdel Noor RA; Shalaby KA; Haroun RA
Saudi J Kidney Dis Transpl; 2021; 32(1):19-29. PubMed ID: 34145111
[TBL] [Abstract][Full Text] [Related]
3. Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study.
Dong X; Zheng Z; Luo X; Ding J; Li Y; Li Z; Li S; Rong M; Fu Y; Wu Z; Zhu P
Medicine (Baltimore); 2018 Apr; 97(16):e0343. PubMed ID: 29668584
[TBL] [Abstract][Full Text] [Related]
4. Combined detection of uMCP-1 and uTWEAK for rapid discrimination of severe lupus nephritis.
Dong XW; Zheng ZH; Ding J; Luo X; Li ZQ; Li Y; Rong MY; Fu YL; Shi JH; Yu LC; Wu ZB; Zhu P
Lupus; 2018 May; 27(6):971-981. PubMed ID: 29451067
[TBL] [Abstract][Full Text] [Related]
5. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases.
Xuejing Z; Jiazhen T; Jun L; Xiangqing X; Shuguang Y; Fuyou L
J Biomed Biotechnol; 2012; 2012():359647. PubMed ID: 22719208
[TBL] [Abstract][Full Text] [Related]
6. Serum and urine TNF-like weak inducer of apoptosis, monocyte chemoattractant protein-1 and neutrophil gelatinase-associated lipocalin as biomarkers of disease activity in patients with systemic lupus erythematosus.
Mirioglu S; Cinar S; Yazici H; Ozluk Y; Kilicaslan I; Gul A; Ocal L; Inanc M; Artim-Esen B
Lupus; 2020 Apr; 29(4):379-388. PubMed ID: 32041504
[TBL] [Abstract][Full Text] [Related]
7. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
Schwartz N; Rubinstein T; Burkly LC; Collins CE; Blanco I; Su L; Hojaili B; Mackay M; Aranow C; Stohl W; Rovin BH; Michaelson JS; Putterman C
Arthritis Res Ther; 2009; 11(5):R143. PubMed ID: 19785730
[TBL] [Abstract][Full Text] [Related]
8. Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory study.
Reyes-Martínez F; Pérez-Navarro M; Rodríguez-Matías A; Soto-Abraham V; Gutierrez-Reyes G; Medina-Avila Z; Valdez-Ortiz R
Nefrologia (Engl Ed); 2018; 38(2):152-160. PubMed ID: 28755900
[TBL] [Abstract][Full Text] [Related]
9. Urinary TWEAK and the activity of lupus nephritis.
Schwartz N; Su L; Burkly LC; Mackay M; Aranow C; Kollaros M; Michaelson JS; Rovin B; Putterman C
J Autoimmun; 2006 Dec; 27(4):242-50. PubMed ID: 17257812
[TBL] [Abstract][Full Text] [Related]
10. Urinary TNF-like weak inducer of apoptosis (TWEAK) as a biomarker of lupus nephritis.
Salem MN; Taha HA; Abd El-Fattah El-Feqi M; Eesa NN; Mohamed RA
Z Rheumatol; 2018 Feb; 77(1):71-77. PubMed ID: 27619369
[TBL] [Abstract][Full Text] [Related]
11. Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare.
Singh RG; Usha ; Rathore SS; Behura SK; Singh NK
Lupus; 2012 Oct; 21(11):1214-8. PubMed ID: 22759858
[TBL] [Abstract][Full Text] [Related]
12. Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study.
Suttichet TB; Kittanamongkolchai W; Phromjeen C; Anutrakulchai S; Panaput T; Ingsathit A; Kamanamool N; Ophascharoensuk V; Sumethakul V; Avihingsanon Y
Lupus Sci Med; 2019; 6(1):e000298. PubMed ID: 31168397
[TBL] [Abstract][Full Text] [Related]
13. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis.
El-Shehaby A; Darweesh H; El-Khatib M; Momtaz M; Marzouk S; El-Shaarawy N; Emad Y
J Clin Immunol; 2011 Oct; 31(5):848-56. PubMed ID: 21691937
[TBL] [Abstract][Full Text] [Related]
14. Serum and Urine Monocyte Chemoattractant Protein-1 as A Markers for Lupus Nephritis.
Abozaid MA; Ahmed GH; Tawfik NM; Sayed SK; Ghandour AM; Madkour RA
Egypt J Immunol; 2020 Jan; 27(1):97-107. PubMed ID: 33180392
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.
Gupta R; Yadav A; Aggarwal A
Clin Rheumatol; 2016 Nov; 35(11):2707-2714. PubMed ID: 27624649
[TBL] [Abstract][Full Text] [Related]
16. TWEAK: a novel biomarker for lupus nephritis?
Dhaun N; Kluth DC
Arthritis Res Ther; 2009; 11(6):133. PubMed ID: 19951398
[TBL] [Abstract][Full Text] [Related]
17. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
[TBL] [Abstract][Full Text] [Related]
18. Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis.
Urrego-Callejas T; Álvarez SS; Arias LF; Reyes BO; Vanegas-García AL; González LA; Muñoz-Vahos CH; Vásquez G; Quintana LF; Gómez-Puerta JA
Clin Rheumatol; 2021 May; 40(5):1853-1859. PubMed ID: 33079302
[TBL] [Abstract][Full Text] [Related]
19. Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios.
Ngamjanyaporn P; Worawichawong S; Pisitkun P; Khiewngam K; Kantachuvesiri S; Nongnuch A; Assanatham M; Sathirapongsasuti N; Kitiyakara C
PLoS One; 2022; 17(3):e0263778. PubMed ID: 35271583
[TBL] [Abstract][Full Text] [Related]
20. Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in Brazilian patients.
Rosa RF; Takei K; Araújo NC; Loduca SM; Szajubok JC; Chahade WH
J Rheumatol; 2012 Oct; 39(10):1948-54. PubMed ID: 22942263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
